Heart attack survivors may think the worst is behind them. But many later develop heart failure, a progressive disease marked by shortness of breath and swelling in the legs. Symptoms can prevent patients from working, exercising—even ...
Jan 28, 2019
0
119
(HealthDay)—Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday.
Nov 29, 2018
0
0
Drug development stakeholders from private and public sectors, including researchers, academics, and representatives from the pharmaceutical industry and advocacy groups, have joined together to call for a significant and ...
Nov 26, 2018
0
0
Cancer treatments are suspected to accelerate certain aging processes in the body. A new study has found that indicators of such biological aging correlate with declines in cognitive function in women who had undergone breast ...
Nov 26, 2018
0
11
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...
Nov 16, 2018
0
74
The selection of a first-line chemotherapy drug to treat many types of cancer is often a clear-cut decision governed by standard-of-care protocols, but what drug should be used next if the first one fails?
Nov 7, 2018
0
90
A new way of identifying potential cancer drugs could streamline the development of therapies, following a discovery by scientists.
Nov 1, 2018
0
0
Researchers have discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer. Reactivation leads to restored tumor suppressor gene expression and enhanced ...
Oct 25, 2018
0
1
Thrombosis-on-a-chip, vasculature-on-a-chip and engineered models of human cardiac fibrosis are just a few of the new technologies revolutionizing research into human cardiovascular disease—a condition responsible for 17 ...
Oct 24, 2018
0
0
A team of researchers led by Principal Investigator Dr. Jan Gruber from Yale-NUS College has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis ...
Oct 22, 2018
1
1804
